InXMed raises $15Mln Series B+ Financing funded by Hyfinity Investments

InxMed Co., Ltd, a clinical-stage biotechnology firm committed to developing innovative therapies steering stroma microenvironment and drug resistance for hard-to-treat solid tumors, recently announced the accomplishment of $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments. InxMed explained that it will utilize the funds to accelerate ongoing clinical trials of […]